InMed Pharmaceuticals Files Proxy Statement

Ticker: INM · Form: DEF 14A · Filed: May 16, 2025 · CIK: 1728328

Sentiment: neutral

Topics: proxy-statement, governance, annual-meeting

TL;DR

InMed Pharma proxy filed. Vote on directors & auditors.

AI Summary

InMed Pharmaceuticals Inc. filed its definitive proxy statement on May 16, 2025, for its annual meeting of shareholders. The filing outlines the proposals to be voted on, including the election of directors and the ratification of the appointment of its independent registered public accounting firm. The company is seeking shareholder approval for these matters to continue its operations and governance.

Why It Matters

This filing is crucial for shareholders as it details the company's governance and provides information necessary for them to vote on important matters affecting the company's future direction.

Risk Assessment

Risk Level: medium — Proxy statements are routine filings, but the specific proposals and the company's financial health can introduce medium risk.

Key Players & Entities

FAQ

What is the purpose of this DEF 14A filing?

The purpose of this DEF 14A filing is to provide shareholders with information regarding the matters to be voted upon at the company's annual meeting, including the election of directors and the ratification of the independent registered public accounting firm.

When was this definitive proxy statement filed?

This definitive proxy statement was filed on May 16, 2025.

What is the company's Central Index Key (CIK)?

The company's Central Index Key (CIK) is 0001728328.

What is the company's fiscal year end?

The company's fiscal year end is June 30 (0630).

Where is InMed Pharmaceuticals Inc. headquartered?

InMed Pharmaceuticals Inc. is headquartered in Vancouver, with its business and mail address listed as 1445-885 West Georgia St., Vancouver, V6C 3E8.

Filing Details

This Form DEF 14A (Form DEF 14A) was filed with the SEC on May 16, 2025 regarding InMed Pharmaceuticals Inc. (INM).

View full filing on EDGAR

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on Read The Filing